Augmedix, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Loss Per Share

Loss Per Share

6 Months Ended

Jun. 30, 2024

Basic net loss per share of common stock is computed by dividing net loss by the weighted average number of common stock outstanding during each period. Diluted net loss per common stock includes the effect, if any, from the potential exercise or conversion of securities, such as options and warrants which would result in the issuance of incremental common stock. In computing basic and diluted net loss per share, the weighted average number of shares is the same for both calculations due to the fact that a net loss existed for the three and six months ended months ended June 30, 2024 and 2023.

The Company calculated basic and diluted net loss per share as follows:


	Three Months Ended June 30,		Six Months Ended June 30,
	2024	2023	2024	2023
Numerator
Net Loss	$(8,450)	$(5,033)	$(14,949)	$(10,272)

Denominator
Weighted average shares, basic and diluted	53,387,349	43,607,984	53,223,008	40,566,425

Net loss per share	$(0.16)	$(0.12)	$(0.28)	$(0.25)

The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:


	June 30, 2024	June 30, 2023
Common stock warrants	4,103,267	4,743,466
Stock options and stock appreciation rights	9,136,058	9,562,621
Restricted stock units	2,069,018	263,155
	15,308,343	14,569,242